Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Neovascular age-related macular degeneration (nAMD) is characterized by pathological angiogenesis that contributes to vision loss. Currently, treatment involves intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, such as bevacizumab and aflibercept. However, nearly 40% of patients are resistant to anti-VEGF monotherapy and progress to more-severe disease in the long term. Now, Yang et al. have developed a bispecific fusion protein (efdamrofusp alfa) that simultaneously targets VEGF and the complement system. This agent showed antiangiogenic activity in mice and nonhuman primates (NHP), and was well tolerated in patients in a phase I clinical trial.